Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
9 papers
Recent·Most cited
C. Chen, Y.-P. Jiang, I. You, N. Gray, R. Z. Lin
This study shows that down-regulating AKT proteins slows mutant-KRAS pancreatic tumor growth more effectively than inhibiting AKT kinase activity.
bioRxiv · May 3, 2024Cancer Biology
R. C. Sarott, S. P. Gourisankar, B. A. Karim, S. Nettles, H. Yang, B. Dwyer, J. M. Simanauskaite, J. Tse, H. Abuzaid, A. Krokhotin, T. Zhang, S. M. Hinshaw, M. R. Green, G. R. Crabtree, N. Gray
The paper develops bivalent molecules that convert kinase inhibitors into activators of proapoptotic genes, achieving selective killing of DLBCL cells with low cytotoxicity.
bioRxiv · Oct 23, 2023 · PreprintCancer Biology
M. M. Hassan, Y.-D. Li, M. W. Ma, M. Teng, W. S. Byun, K. Puvar, R. Lumpkin, B. Sandoval, J. C. Rutter, C. Y. Jin, M. Y. Wang, S. Xu, A. M. Schmoker, H. Cheong, B. J. Groendyke, , N. Gray
This study evaluates how electrophilic modifications to JQ1 affect DCAF16 trans-labeling and BRD4 degradation, showing a correlation between warhead exposure and degradation efficiency.
bioRxiv · Oct 7, 2023 · PreprintPharmacology & Toxicology
Y. Kim, C. Seo, E. Jeon, I. You, K. Hwang, N. Kim, H.-S. Choi, S. M. Hinshaw, T. Sim, N. Gray
This study demonstrates the use of KLHDC2 as a substrate adaptor for targeted protein degradation using peptide-based bivalent compounds.
bioRxiv · Dec 17, 2022Biochemistry
E. Erickson, I. You, G. Perry, A. Dugourd, K. Donovan, C. Crafter, J. Johannes, S. Williamson, J. Moss, S. Ros, R. Ziegler, S. Barry, E. Fischer, N. Gray, R. Madsen, A. Toker
This study develops a second-generation AKT degrader, INY-05-040, showing improved efficacy over existing inhibitors in breast cancer cells by inducing stress MAPK signaling.
bioRxiv · Oct 11, 2022 · PreprintCancer Biology
M. Fan, W. Lu, J. Che, N. P. Kwiatkowski, Y. Gao, H.-S. Seo, S. B. Ficarro, P. C. Gokhale, Y. Liu, E. A. Geffken, J. Lakhani, K. Song, M. Kuljanin, W. Ji, J. Jiang, , N. Gray
This paper develops a covalent inhibitor of the YAP-TEAD complex, demonstrating its ability to suppress Hippo signaling defects and inhibit cancer cell growth.
bioRxiv · May 10, 2022Cancer Biology
Y. Tarumoto, S. Lin, J. Wang, J. Milazzo, Y. Xu, N. Gray, K. Stegmaier, C. Vakoc
This study shows that the SIK3 inhibitor YKL-05-099 suppresses MEF2C function and slows AML progression in mouse models.
bioRxiv · May 14, 2019 · PreprintCancer Biology
M. Morotti, E. Bridges, A. Valli, H. Choudhry, H. Sheldon, S. Wigfield, N. Gray, D. Jones, E. J. Teoh, W.-C. Cheng, S. Lord, S. Haider, A. Mcintyre, D. C. I. Goberdhan, F. Buffa, A. L. Harris
This study shows hypoxia shifts SNAT2 regulation from ER to HIF-1 in breast cancer, leading to endocrine resistance and poor outcomes.
bioRxiv · Aug 3, 2018Cancer Biology
D. H. Drewry, C. I. Wells, D. M. Andrews, R. Angell, H. Al-Ali, A. D. Axtman, S. J. Capuzzi, J. M. Elkins, P. Ettmayer, M. Frederiksen, O. Gileadi, N. Gray, A. Hooper, S. Knapp, S. Laufer, , T. M. Willson
The paper shares progress on a kinase chemogenomic set, releases inhibitor profiling data, and calls for community collaboration to complete the set.
bioRxiv · Jan 31, 2017Pharmacology & Toxicology